First Clade I Mpox Case Detected in New York City

• American Medical Association warns that $100,000 H-1B visa application fees jeopardize physician recruitment for rural and underserved U.S. areas. • Costs deter international doctors, who fill 25% of rural positions, exacerbating provider shortages affecting 60 million Americans. • AMA urges policy reform to maintain care access amid growing demand.

• Public health officials confirmed two cases of measles in Sacramento County, California, amid ongoing monitoring for potential spread. • The cases highlight persistent risks despite national vaccination efforts, with officials urging unvaccinated residents to seek immunization. • Measles outbreaks underscore gaps in herd immunity, particularly in localized communities, prompting heightened surveillance statewide.

• The CDC reported six more US children died from influenza last week, bringing the season's pediatric flu deaths to 149 as respiratory virus activity slows nationwide. • About 85% of deceased children with known vaccination status were unvaccinated, with flu positivity in labs dropping to 4.7% and hospitalizations falling to 1.3 per 100,000 people. • Influenza B now predominates after surpassing A viruses, with high wastewater levels of RSV, influenza B, rotavirus, and norovirus signaling ongoing risks.

• President Trump issued an Executive Order directing the Department of Health and Human Services to expedite access to treatments for patients with serious mental illness. • The FDA is accelerating its review process for mental health therapies in response to the directive. • This policy shift aims to reduce barriers to treatment approval and expand therapeutic options for affected patients.

• The U.S. daily COVID-19 case average increased by 13.3% over the past week, though hospitalizations continue to decline according to federal data. • About 48,000 patients are currently hospitalized with COVID-19, representing a decrease of nearly 104,000 patients over the past eight weeks, with hospital admissions down 11.7% weekly. • Alaska has the highest infection rate in the nation, followed by Montana, North Dakota, and Wyoming, while Puerto Rico, Florida, and Hawaii report the lowest rates.

• A multiyear international campaign is underway to repair damage to childhood immunization efforts caused by the COVID-19 pandemic. • The initiative focuses on restoring vaccination rates that declined during the pandemic period across multiple countries. • Public health experts view this effort as critical to preventing resurgence of vaccine-preventable diseases in vulnerable pediatric populations.

• The Trump administration will require all 50 states to explain their plans to revalidate Medicaid providers as part of a national escalation of anti-fraud efforts, announced by Dr. Mehmet Oz on Tuesday. • This marks a significant expansion from previous anti-fraud initiatives that have largely focused on specific states rather than a nationwide mandate. • The move aims to strengthen program integrity and reduce fraudulent claims across the Medicaid system.

• President Trump signed an executive order directing federal regulators to fast-track FDA review of psychedelic drugs including psilocybin and ibogaine for treating depression, anxiety, and PTSD. • The order allocates $50 million in federal funds to states implementing or developing psychedelic treatment programs as part of a federal-state partnership initiative. • Trump highlighted that over 14 million American adults have serious mental illness, with approximately 8 million on prescription medication, framing psychedelics as addressing a national mental health crisis including suicide prevention.

• The FDA announced it will issue national priority vouchers for three psychedelic drugs next week, marking the first time the agency has fast-tracked any psychedelics for review under Trump's executive order on mental health reform. • The vouchers can compress FDA review timelines from several months to just weeks, according to FDA Commissioner Marty Makary, if the drugs align with national priorities. • Trump's order directs $50 million in federal funding to states developing psychedelic treatment programs and establishes a federal-state partnership for technical assistance and data sharing.

• The FDA announced the first ibogaine investigational new drug application as part of Trump's mental health executive order accelerating psychedelic drug approvals and research pathways. • HHS will coordinate with the FDA and DEA to expedite research approval and clinical trial access for emerging mental health treatments under strict medical supervision and scientific oversight. • The initiative specifically targets treatment-resistant conditions and addresses mental health needs among veterans and patients who have not responded to conventional therapies.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.